Revolutionizing Respiratory Papillomatosis Treatment: Precigen Achieves Landmark Commercial Launch Milestone with Papzimeos
Precigen has made history in the medical field with its pioneering commercial launch of Papzimeos, a groundbreaking therapeutic agent for adult recurrent respiratory papillomatosis (RRP). In a significant milestone for patients and healthcare providers alike, this first-ever therapeutic commercial launch in RRP marks a substantial advancement in the treatment landscape.
As Helen Sabzevari, President and CEO of Precigen, noted during the company's Q4 2025 update call, "We are seeing tremendous progress with the first-ever therapeutic commercial launch in RRP... This substantial advancement constitutes a pivotal milestone for all stakeholders impacted by RRP."
The launch has been met with strong enthusiasm from prescribers at major medical centers and community practices, leading to a robust uptake of Papzimeos. According to Sabzevari, "As we are only a few days away from completion of Q1, which is the first full quarter of Papzimeos commercial sales, we think it is helpful to provide investors with color on the Papzimeos sales ramp-up."
Notably, net product revenue for Q4 2025 was $3.4 million, with shipments commencing in November. As a result, based on commercial activity to date, Precigen expects revenues in Q1 to exceed $18 million.
The success of Papzimeos can be attributed to its unprecedented clinical data, including unmatched efficacy and durability of responses, as well as its mechanism of action that addresses the root cause of RRP by eliciting a targeted immune response against HPV 6 and 11. As Sabzevari highlighted, "Papzimeos directly addresses the root cause of RRP... We have significantly raised the bar for any future competitor entering the adult RRP space."
With Papzimeos receiving full FDA approval with a broad label for adult RRP, patients and physicians alike are now able to benefit from this revolutionary therapy. As a result of its transformative clinical data, Papzimeos has been endorsed by expert consensus papers sponsored by the RRP Foundation, recommending it as the first immunotherapy and preferred first-line treatment for adults with recurrent respiratory papillomatosis.
The launch of Papzimeos represents a pivotal advancement for the RRP community, prioritizing medical therapy over repeated surgical interventions to improve patients' outcomes. This achievement is a testament to Precigen's dedication to advancing cutting-edge treatments that transform lives.
